AxoGen, Inc. (NASDAQ:AXGN)’s earnings report is awaited on April, 29., according to Faxor. Analysts forecast $-0.20 EPS. That’s $0.09 down or 81.82 % from 2018’s earnings of $-0.11. After $-0.13 EPS was revealed previous quarter, analysts now see negative EPS growth of 53.85 % for AxoGen, Inc.. Ticker’s shares touched $21.01 during the last trading session after 0.24% change.AxoGen, Inc. has volume of 235,751 shares. Since April 2, 2018 AXGN has declined 40.68% and is downtrending. AXGN underperformed by 45.05% the S&P 500.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

In total 3 analysts cover AxoGen (NASDAQ:AXGN). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:AXGN)’s analyst reports since October 30, 2018 according to StockzIntelligence Inc. On Tuesday, October 30 the rating was maintained by Cantor Fitzgerald with “Overweight”. On Wednesday, February 27 the stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Buy” rating by Jefferies. On Wednesday, February 27 the firm has “Buy” rating by Cantor Fitzgerald given. The company rating was upgraded by BTIG Research on Monday, March 25.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The company has $818.23 million market cap. The company's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Currently it has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

For more AxoGen, Inc. (NASDAQ:AXGN) news brought out briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “CLASS ACTION UPDATE for AXGN, ATVI, GSM and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – GlobeNewswire” brought out on March 05, 2019, “Axogen, Inc. to Participate at Upcoming February Investor Conferences – GlobeNewswire” on February 19, 2019, “AxoGen beats by $0.01, misses on revenue – Seeking Alpha” with a publish date: February 26, 2019, “The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AXGN, ATVI, CTL and INGN – GlobeNewswire” and the last “Axogen, Inc. to Participate at Upcoming March Investor Conferences – GlobeNewswire” with publication date: March 04, 2019.